Evidence map›Paper›PMID 24078173›Full record

ArticleJournal of neuro-oncology2014

Fractionated stereotactic radiosurgery for recurrent ependymoma in children.

Lindsey M Hoffman, S Reed Plimpton, Nicholas K Foreman, Nicholas V Stence, Todd C Hankinson, Michael H Handler, Molly S Hemenway, Rajeev Vibhakar, Arthur K Liu

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Journal of neuro-oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03841435 (Feasibility Study of Hypofractionated Radiotherapy in the Setting of Recurrent Diffuse Intrinsic Pontine Glioma), which is not on this map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03841435 nacompletednot on this mapstarted 2018, after this paper: background citation

Feasibility Study of Hypofractionated Radiotherapy in the Setting of Recurrent Diffuse Intrinsic Pontine Glioma

TypeinterventionalSponsorUniversity of CincinnatiRan2018 to 2023Enrolled5ConditionsRecurrent Diffuse Intrinsic Pontine GliomaArmsHypofractionated Radiotherapy
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Trial
  4. Review
  5. Review
  6. Ependymoma: Evaluation and Management Updates.Current oncology reports · 2022
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Pediatric Brain Tumors: Current Knowledge and Therapeutic Opportunities.Journal of pediatric hematology/oncology · 2016
    Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Lindsey M Hoffman
S Reed Plimpton
Nicholas K Foreman
Nicholas V Stence
Todd C Hankinson
Michael H Handler
Molly S Hemenway
Rajeev Vibhakar
Arthur K Liu
University of Colorado Anschutz Medical Campus · USUniversity of Colorado Denver · USChildren's Hospital Colorado · US

Funding

Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
POSTGRADUATE TRAINING IN PEDIATRIC ONCOLOGYT32CA082086 · NCI · UNIVERSITY OF COLORADO DENVER · PI GORE, LIA · 2000 to 2015
$4.1M
NCATS NIH HHS UL1 TR001082NCI NIH HHS T32 CA082086NCI NIH HHS T32 CA 82086-13
6 · The paper itself

Abstract

Outcomes for children with relapsed ependymoma are poor. Re-irradiation is a potentially viable salvage option in these patients. Data were reviewed for 12 patients (median age 5.6 years) with relapsed ependymoma who received fractionated stereotactic radiosurgery (fSRS) following maximal surgical resection from 1995 to 2012. Four patients experienced a second recurrence, including 2 in-field and 2 distant failures. Median time to second recurrence (32 months) was significantly longer than time to first recurrence (24 months) (p = 0.008). Three-year local control was 89 %, and median event free survival from fSRS was 3.4 years. Radiation necrosis was observed in 6 patients, 3 who were symptomatic. In conclusion, fSRS offers durable response with a tolerable toxicity profile in children with recurrent EPN.

Indexed as

AdolescentBrain NeoplasmsChildChild, PreschoolEpendymomaHumansInfantKaplan-Meier EstimateNeoplasm Recurrence, LocalRadiosurgeryTreatment Outcome

Identifiers

PMID24078173
PMCPMC3946261
OpenAlexW2019062644

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.